Morris Plains-based Immunomedics Inc., a clinical-stage biopharmaceutical company, announced Monday it has appointed Robert Iannone as head of research and development and chief medical officer, effective immediately.
In this role, Iannone will head all clinical development, regulatory, pre-clinical, translational research and medical affairs at the company.
“Rob is not only a highly accomplished oncology drug developer, but also is deeply rooted in science with outstanding development experience and an established track record in a number of disease settings of interest to Immunomedics. We are thrilled that Rob is bringing his strong industry, medical, scientific and strategic leadership to Immunomedics,” said Michael Pehl, CEO and president. “Through his unique expertise, Rob will be instrumental in aggressively advancing development of our programs with the right drug combinations and in the most appropriate patient segments. I look forward to working closely with Rob to unlock the full potential of our ADC platform and further strengthen Immunomedics as a leader in this field.”
Iannone, who has 13 years of experience in clinical drug development, was most recently senior vice president and head of immuno-oncology, global medicines development at AstraZenica/MedImmune. Before that he was executive director, clinical research and section head of oncology at Merck Research Laboratories.
“Immunomedics has a unique and highly differentiated ADC pipeline and platform technology. I am very excited to be joining the company,” Iannone said.
